The present invention relates to compounds of formula (I-VII)
or a pharmaceutically acceptable salt or prodrug thereof, in which A, L, R
6
, R
7
and R
8
are defined herein. The present invention also relates to methods of trating pain using these compounds and pharmaceutical compositions including these compounds.
The present invention relates to compounds of formula (I-VII)
or a pharmaceutically acceptable salt or prodrug thereof, in which A, L, R
6
, R
7
and R
8
are defined herein. The present invention also relates to methods of treating pain using these compounds and pharmaceutical compositions including these compounds.
Substituted phenyloxazolidinones for antimicrobial therapy
申请人:The Global Alliance for TB Drug Development, Inc.
公开号:US10550092B2
公开(公告)日:2020-02-04
The present invention relates to novel oxazolidinones (Formula I): or a pharmaceutically acceptable salt having ring A characterized by N-containing monocyclic, bicyclic or spirocyclic substituents, to their preparation, and to their use as drugs for treating Mycobacterium tuberculosis and other microbial infections, either alone or in combination with other anti-infective treatments.
本发明涉及新型噁唑烷酮(式Ⅰ):或具有以含 N 的单环、双环或螺环取代基为特征的环 A 的药学上可接受的盐,涉及它们的制备,以及它们作为治疗结核分枝杆菌和其他微生物感染的药物的用途,可以单独使用,也可以与其他抗感染治疗药物联合使用。
BENZISOTHIAZOLE-1, 1-DIOXIDE ACTING AS ANTAGONISTS TO THE VANILLOID RECEPTOR SUBTYPE 1 (VR1) AND USES THEREOF
申请人:Abbott Laboratories
公开号:EP1836200B1
公开(公告)日:2012-05-16
SUBSTITUTED PHENYLOXAZOLIDINONES FOR ANTIMICROBIAL THERAPY
申请人:The Global Alliance for TB Drug Development, Inc.
公开号:US20180179168A1
公开(公告)日:2018-06-28
The present invention relates to novel oxazolidinones (Formula I): or a pharmaceutically acceptable salt having ring A characterized by N-containing monocyclic, bicyclic or spirocyclic substituents, to their preparation, and to their use as drugs for treating
Mycobacterium tuberculosis
and other microbial infections, either alone or in combination with other anti-infective treatments.